Lynch Syndrome Clinical Trials 2023

What are the top hospitals conducting lynch syndrome research?

Lynch syndrome, a hereditary condition associated with an increased risk of certain cancers, is receiving focused attention at several top hospitals across the United States. In Atlanta, Emory University Hospital and its Winship Cancer Institute lead the way with an impressive 13 ongoing clinical trials dedicated to understanding and treating this syndrome. Despite having only one previously recorded trial in their history dating back to 2005, their commitment to research remains unwavering. Meanwhile, M D Anderson Cancer Center in Houston boasts both a strong presence and extensive experience in studying lynch syndrome. With 12 active trials currently underway and eight previous trials conducted since their inaugural study in 2005.

In New york City's renowned Memorial Sloan Kettering Cancer Center, researchers are engaged in pushing the boundaries of knowledge surrounding lynch syndrome through their participation in eleven ongoing clinical trials as well as four completed studies that date all the way back to 2004. The Mayo Clinic's Arizona branch located in Scottsdale contributes significantly too—it has eight active lynch syndrome trials running alongside three earlier endeavors initiated starting from 2005.

Lastly, Duke University Medical Center located conveniently at Durham joins these prestigious institutions by actively participating with eight current lynch syndrome clinical tests while contributing towards two prior investigations which they embarked on since recording first such case trial also dated back around similar time period of early- mid-2000s .

These leading hospitals exemplify the dedication and momentum driving research on Lynch Syndrome nationwide. By continually expanding our understanding of this condition through cutting-edge clinical trials, scientists strive for improved prevention strategies and better treatment options for individuals impacted by Lynch Syndrome—a true testament to medical progress fueled by tireless efforts within diverse locations throughout the United States

Which are the best cities for lynch syndrome clinical trials?

Los Angeles, California; Boston, Massachusetts; and Atlanta, Georgia are the top cities for lynch syndrome clinical trials. Los Angeles leads with 43 active trials investigating treatments like Nivolumab and Eflornithine plus sulindac. In Boston, there are 37 ongoing studies focusing on interventions such as Radiation Therapy and pembrolizumab. Atlanta follows closely behind with 30 active trials exploring options like Radiation Therapy and Anti-SEMA4D Monoclonal Antibody VX15/2503. These cities offer individuals affected by lynch syndrome access to cutting-edge clinical trials that contribute to advancements in treatment options for this condition.

Which are the top treatments for lynch syndrome being explored in clinical trials?

Exciting developments are underway in the clinical trials exploring treatments for Lynch syndrome. Nivolumab, a promising drug, is currently being investigated in four active trials dedicated to this condition. Since its introduction in 2018, it has already made waves with two all-time Lynch syndrome trials. Another contender on the forefront is pembrolizumab, which is involved in three ongoing trials and was first listed as a potential treatment option back in 2015. These groundbreaking therapies hold immense potential to revolutionize the management of Lynch syndrome and improve outcomes for those affected by this hereditary disorder.

What are the most recent clinical trials for lynch syndrome?

Recent clinical trials have brought new possibilities in the treatment of lynch syndrome, a hereditary condition that increases the risk of various cancers. One such trial evaluated Fluorine F 18 L-glutamate Derivative BAY94-9392, an investigational drug aimed at targeting specific genetic mutations associated with lynch syndrome. Another promising study explored Dasatinib, a medication known for its potential to inhibit cancer cell growth. Additionally, Pemigatinib and Dabrafenib were investigated in separate trials as potential treatments for lynch syndrome-related cancers. These innovative approaches offer hope for improved outcomes and tailored therapies for individuals affected by this genetic disorder.

What lynch syndrome clinical trials were recently completed?

Recently completed clinical trials focused on Lynch syndrome have made significant strides in advancing our understanding and treatment of this hereditary condition. One notable trial, sponsored by the National Cancer Institute (NCI), concluded recently and yielded important insights into targeted therapies for Lynch syndrome-related cancers. This breakthrough study holds promise for individuals with Lynch syndrome and highlights the ongoing commitment of researchers to improve outcomes for those affected by this inherited disorder.